Gilead’s Quad Makes It Through FDA Panel Review Despite Renal Safety Concerns
This article was originally published in The Pink Sheet Daily
Antiviral Drugs Advisory Committee votes 13-1 in favor of the four-drug-in-one HIV treatment. Panel members offer a host of suggestions for post-marketing studies, including determining the best means for detecting Quad-related renal injury early.
You may also be interested in...
Mutation Resistance Could Differentiate Shionogi/ViiV’s Dolutegravir
Full data from the Phase III SPRING-2 trial released at the International AIDS Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.
Renal Safety In The Spotlight At FDA Panel Review Of Gilead’s Quad
The four-drug, single-tablet HIV treatment regimen was associated with higher rates of serious adverse events and study drug discontinuations due to renal events in the pivotal trials. FDA is seeking the Antiviral Drugs Advisory Committee’s views on renal safety and whether monitoring recommendations should be stricter than those proposed by Gilead.
Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits
Reduction in the risk of hypoglycemia level 2 and 3 events, along with either a reduction or maintenance of an acceptable hemoglobin A1C, is a clinically relevant efficacy endpoint for drug development in Types 1 and 2 diabetes, FDA states in new draft guidance.